{"hands_on_practices": [{"introduction": "Computed Tomography (CT) is a cornerstone of modern diagnostic imaging, but the grayscale values in a CT image are not arbitrary. They represent quantitative measurements on the Hounsfield Unit (HU) scale, which is directly linked to the physical property of X-ray attenuation. This exercise walks through the first-principles derivation of the HU scale, demonstrating how this standardized system provides a universal language for interpreting tissue density and differentiating materials like fluid, soft tissue, and gas [@problem_id:4653972].", "problem": "A patient with multilobar bacterial pneumonia is evaluated using Computed Tomography (CT). In CT, reconstruction is based on the Beer–Lambert law, where transmitted intensity through a homogeneous slab of thickness $x$ is $I = I_{0}\\exp(-\\mu x)$, and $\\mu$ is the linear attenuation coefficient. Voxels in the reconstructed image are assigned a dimensionless index called the Hounsfield Unit (HU), which is defined by a linear mapping of the effective voxel attenuation relative to a standard reference material. Assume the following constraints are imposed by clinical convention for the HU scale: water is assigned $0$ HU, and a material with negligible attenuation at diagnostic X-ray energies (effectively $\\mu = 0$) is assigned $-1000$ HU. \n\nStarting from the Beer–Lambert law and the definition of $\\mu$ as the linear attenuation coefficient, construct the unique affine mapping from a measured $\\mu$ to HU that satisfies these constraints. Then, for a tissue with effective attenuation coefficient $\\mu_{t} = 0.020\\,\\text{mm}^{-1}$ at the scanner’s effective energy and reference water attenuation $\\mu_{\\text{water}} = 0.019\\,\\text{mm}^{-1}$, compute the HU value. Express your final answer as a dimensionless quantity and round to $4$ significant figures.", "solution": "The problem requires the construction of an affine mapping from the linear attenuation coefficient, $\\mu$, to the Hounsfield Unit, $\\text{HU}$, and then the calculation of the $\\text{HU}$ for a specific tissue.\n\nFirst, the problem statement is validated.\nGivens:\n1.  The relationship between transmitted intensity $I$, initial intensity $I_{0}$, linear attenuation coefficient $\\mu$, and thickness $x$ is the Beer–Lambert law: $I = I_{0}\\exp(-\\mu x)$.\n2.  The Hounsfield Unit, $\\text{HU}$, is defined by a linear (affine) mapping of the effective voxel attenuation coefficient, $\\mu$.\n3.  Constraint 1: For water, with attenuation coefficient $\\mu_{\\text{water}}$, the assigned value is $0\\,\\text{HU}$. Thus, $\\text{HU}(\\mu_{\\text{water}}) = 0$.\n4.  Constraint 2: For a material with negligible attenuation, $\\mu = 0$, the assigned value is $-1000\\,\\text{HU}$. Thus, $\\text{HU}(0) = -1000$.\n5.  The attenuation coefficient for the tissue is $\\mu_{t} = 0.020\\,\\text{mm}^{-1}$.\n6.  The reference attenuation coefficient for water is $\\mu_{\\text{water}} = 0.019\\,\\text{mm}^{-1}$.\n\nValidation:\nThe problem is scientifically grounded, based on the fundamental principles of X-ray attenuation and the definition of the Hounsfield scale used in computed tomography. The problem is well-posed, providing two distinct constraints that uniquely determine the two parameters of a linear (affine) function. All necessary data are provided, the constraints are consistent with the established definition of $\\text{HU}$, and the values are physically realistic. The problem is therefore deemed valid.\n\nThe affine mapping between $\\mu$ and $\\text{HU}$ can be written in the general form:\n$$\n\\text{HU}(\\mu) = K \\mu + C\n$$\nwhere $K$ and $C$ are constants to be determined. We use the two given constraints to solve for these constants.\n\nConstraint 1: $\\text{HU}(\\mu_{\\text{water}}) = 0$.\nSubstituting into the equation gives:\n$$\nK \\mu_{\\text{water}} + C = 0 \\quad (1)\n$$\n\nConstraint 2: $\\text{HU}(0) = -1000$.\nSubstituting into the equation gives:\n$$\nK (0) + C = -1000\n$$\nThis directly yields the value of the constant $C$:\n$$\nC = -1000\n$$\n\nNow, we substitute the value of $C$ back into equation $(1)$:\n$$\nK \\mu_{\\text{water}} + (-1000) = 0\n$$\nSolving for $K$:\n$$\nK \\mu_{\\text{water}} = 1000\n$$\n$$\nK = \\frac{1000}{\\mu_{\\text{water}}}\n$$\n\nWith both constants determined, the unique affine mapping is:\n$$\n\\text{HU}(\\mu) = \\left(\\frac{1000}{\\mu_{\\text{water}}}\\right) \\mu - 1000\n$$\nThis expression can be rearranged to a more standard form:\n$$\n\\text{HU}(\\mu) = 1000 \\left( \\frac{\\mu}{\\mu_{\\text{water}}} - 1 \\right) = 1000 \\left( \\frac{\\mu - \\mu_{\\text{water}}}{\\mu_{\\text{water}}} \\right)\n$$\nThis derived formula is the standard definition of the Hounsfield scale, confirming the correctness of our derivation.\n\nNext, we compute the $\\text{HU}$ value for the specified tissue with attenuation coefficient $\\mu_t = 0.020\\,\\text{mm}^{-1}$, using the reference water attenuation $\\mu_{\\text{water}} = 0.019\\,\\text{mm}^{-1}$. We substitute these values into the derived formula:\n$$\n\\text{HU}(\\mu_t) = 1000 \\left( \\frac{\\mu_t - \\mu_{\\text{water}}}{\\mu_{\\text{water}}} \\right)\n$$\n$$\n\\text{HU}(\\mu_t) = 1000 \\left( \\frac{0.020\\,\\text{mm}^{-1} - 0.019\\,\\text{mm}^{-1}}{0.019\\,\\text{mm}^{-1}} \\right)\n$$\nThe units of $\\text{mm}^{-1}$ in the numerator and denominator cancel out, rendering the result dimensionless as required for $\\text{HU}$.\n$$\n\\text{HU}(\\mu_t) = 1000 \\left( \\frac{0.001}{0.019} \\right)\n$$\n$$\n\\text{HU}(\\mu_t) = \\frac{1000}{19}\n$$\nPerforming the division to obtain a numerical value:\n$$\n\\text{HU}(\\mu_t) \\approx 52.6315789...\n$$\nThe problem requires the final answer to be rounded to $4$ significant figures.\n$$\n\\text{HU}(\\mu_t) \\approx 52.63\n$$", "answer": "$$\\boxed{52.63}$$", "id": "4653972"}, {"introduction": "Moving beyond anatomical imaging, advanced MRI sequences like Diffusion-Weighted Imaging (DWI) offer quantitative physiological insights. The Apparent Diffusion Coefficient (ADC) is a powerful biomarker reflecting water molecule mobility, which is often restricted in the viscous, cellular environment of a pyogenic abscess compared to a necrotic tumor. This practice challenges you to use a Bayesian framework to formally solve this common diagnostic dilemma, calculating the precise probability that a lesion is an abscess based on its ADC value [@problem_id:4653915].", "problem": "A patient with fever and focal neurological deficits undergoes Magnetic Resonance Imaging (MRI) with Diffusion-Weighted Imaging (DWI). The Apparent Diffusion Coefficient (ADC) is measured in a ring-enhancing lesion and found to be $0.7 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$. In infectious diseases imaging, pyogenic abscesses typically exhibit restricted diffusion due to the high viscosity and cellularity of pus, yielding lower ADC values, whereas necrotic tumors often have higher ADC values corresponding to less restricted diffusion. Empirically, the ADC distributions reported across peer-reviewed studies for intracranial pyogenic abscess and necrotic tumors fall into disjoint central tendencies with some overlap; for modeling, assume the following Gaussian class-conditional densities for ADC (chosen to be consistent with widely reported ranges):\n\n- Abscess: mean $\\mu_{A} = 0.65 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$ and standard deviation $\\sigma_{A} = 0.10 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n- Necrotic tumor: mean $\\mu_{T} = 1.40 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$ and standard deviation $\\sigma_{T} = 0.20 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n\nAssume prior probabilities reflecting a mixed tertiary-care cohort of ring-enhancing lesions in immunocompetent adults: $P(A) = 0.4$ for abscess and $P(T) = 0.6$ for necrotic tumor. Let $x$ denote the observed ADC value. Using first principles of probability, compute the posterior probability $P(A \\mid x)$ under the Gaussian model for the class-conditional densities and the stated priors. Express the final probability as a decimal (unitless) and round your answer to four significant figures.", "solution": "The problem will first be validated for scientific and logical integrity.\n\n### Step 1: Extract Givens\nThe data and conditions explicitly provided in the problem statement are:\n-   Observed Apparent Diffusion Coefficient (ADC) value: $x = 0.7 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n-   The two possible classes for the lesion are Abscess (A) and Necrotic Tumor (T).\n-   The class-conditional probability densities are modeled as Gaussian distributions.\n-   For an Abscess (A):\n    -   Mean ADC: $\\mu_{A} = 0.65 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n    -   Standard deviation of ADC: $\\sigma_{A} = 0.10 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n-   For a Necrotic Tumor (T):\n    -   Mean ADC: $\\mu_{T} = 1.40 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n    -   Standard deviation of ADC: $\\sigma_{T} = 0.20 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$.\n-   Prior probabilities for the classes:\n    -   $P(A) = 0.4$.\n    -   $P(T) = 0.6$.\n-   The task is to compute the posterior probability $P(A \\mid x)$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is a well-defined Bayesian classification task.\n-   **Scientifically Grounded**: The problem is set in the context of medical imaging (neuroradiology) and uses principles of diffusion-weighted MRI, a standard clinical tool. The ADC values and their distributions for pyogenic abscesses and necrotic tumors are consistent with published clinical data. The application of Bayesian statistics for differential diagnosis is a standard and valid method in medical decision-making. The problem is free of pseudoscience.\n-   **Well-Posed**: All necessary information is provided: the observed data point ($x$), the models for the likelihoods (Gaussian distributions with specified parameters $\\mu$ and $\\sigma$), and the prior probabilities. The sum of the priors is $P(A) + P(T) = 0.4 + 0.6 = 1.0$, which is consistent. The problem asks for a single, uniquely determinable quantity, the posterior probability.\n-   **Objective**: The problem is stated in precise, quantitative terms. The models and parameters are explicitly defined, leaving no room for subjective interpretation.\n-   The problem is complete, consistent, realistic, and formally structured. It does not violate any of the specified invalidity criteria.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A complete solution will be provided.\n\n### Solution\nThe objective is to calculate the posterior probability $P(A \\mid x)$, which is the probability that the lesion is an abscess given the measured ADC value $x$. This is achieved using Bayes' theorem:\n\n$$P(A \\mid x) = \\frac{P(x \\mid A) P(A)}{P(x)}$$\n\nwhere:\n-   $P(x \\mid A)$ is the likelihood of observing the ADC value $x$ given that the lesion is an abscess.\n-   $P(A)$ is the prior probability of an abscess.\n-   $P(x)$ is the evidence, or the marginal probability of observing the ADC value $x$.\n\nThe evidence $P(x)$ is calculated by marginalizing over all possible classes using the law of total probability:\n$$P(x) = P(x \\mid A) P(A) + P(x \\mid T) P(T)$$\n\nSubstituting this into Bayes' theorem gives the full expression for the posterior probability:\n$$P(A \\mid x) = \\frac{P(x \\mid A) P(A)}{P(x \\mid A) P(A) + P(x \\mid T) P(T)}$$\n\nThe problem states that the class-conditional densities, $P(x \\mid A)$ and $P(x \\mid T)$, are Gaussian probability density functions (PDFs). The general form of a Gaussian PDF is:\n$$f(y; \\mu, \\sigma) = \\frac{1}{\\sigma \\sqrt{2\\pi}} \\exp\\left(-\\frac{(y-\\mu)^2}{2\\sigma^2}\\right)$$\n\nFor the abscess class (A), the likelihood is:\n$P(x \\mid A) = \\frac{1}{\\sigma_A \\sqrt{2\\pi}} \\exp\\left(-\\frac{(x-\\mu_A)^2}{2\\sigma_A^2}\\right)$\n\nFor the necrotic tumor class (T), the likelihood is:\n$P(x \\mid T) = \\frac{1}{\\sigma_T \\sqrt{2\\pi}} \\exp\\left(-\\frac{(x-\\mu_T)^2}{2\\sigma_T^2}\\right)$\n\nLet us define the terms in the exponents. To simplify the calculation, we can work with the numerical values without the common factor of $10^{-3}\\,\\text{mm}^2/\\text{s}$, as it will cancel out in the standardized variables. Let the scaled values be $x' = 0.7$, $\\mu'_A = 0.65$, $\\sigma'_A = 0.10$, $\\mu'_T = 1.40$, and $\\sigma'_T = 0.20$.\n\nThe exponent for the abscess likelihood is:\n$$-\\frac{(x-\\mu_A)^2}{2\\sigma_A^2} = -\\frac{(0.7 \\times 10^{-3} - 0.65 \\times 10^{-3})^2}{2(0.10 \\times 10^{-3})^2} = -\\frac{(0.05)^2}{2(0.10)^2} = -\\frac{0.0025}{2(0.01)} = -\\frac{0.0025}{0.02} = -0.125$$\n\nThe exponent for the tumor likelihood is:\n$$-\\frac{(x-\\mu_T)^2}{2\\sigma_T^2} = -\\frac{(0.7 \\times 10^{-3} - 1.40 \\times 10^{-3})^2}{2(0.20 \\times 10^{-3})^2} = -\\frac{(-0.70)^2}{2(0.20)^2} = -\\frac{0.49}{2(0.04)} = -\\frac{0.49}{0.08} = -6.125$$\n\nNow, we substitute these into the likelihood expressions. Let's denote the numerator of the posterior probability as $N_A = P(x \\mid A) P(A)$ and the term for the tumor in the denominator as $D_T = P(x \\mid T) P(T)$.\n\n$$N_A = \\left( \\frac{1}{\\sigma_A \\sqrt{2\\pi}} \\exp(-0.125) \\right) P(A) = \\frac{0.4}{0.10 \\times 10^{-3} \\sqrt{2\\pi}} \\exp(-0.125)$$\n$$D_T = \\left( \\frac{1}{\\sigma_T \\sqrt{2\\pi}} \\exp(-6.125) \\right) P(T) = \\frac{0.6}{0.20 \\times 10^{-3} \\sqrt{2\\pi}} \\exp(-6.125)$$\n\nThe formula for the posterior probability is $P(A \\mid x) = \\frac{N_A}{N_A + D_T}$. The common factor of $\\frac{1}{10^{-3}\\sqrt{2\\pi}}$ will cancel if we factor it out correctly. Alternatively, we can see that the ratio of the terms depends on the pre-factors $P(\\text{class})/\\sigma_{\\text{class}}$ and the exponentials.\n\nLet's compute the ratio $\\frac{D_T}{N_A}$:\n$$\\frac{D_T}{N_A} = \\frac{\\frac{0.6}{\\sigma_T}}{\\frac{0.4}{\\sigma_A}} \\frac{\\exp(-6.125)}{\\exp(-0.125)} = \\frac{0.6 \\times \\sigma_A}{0.4 \\times \\sigma_T} \\exp(-6.125 - (-0.125))$$\n$$\\frac{D_T}{N_A} = \\frac{0.6 \\times (0.10 \\times 10^{-3})}{0.4 \\times (0.20 \\times 10^{-3})} \\exp(-6) = \\frac{0.06}{0.08} \\exp(-6) = \\frac{3}{4} \\exp(-6)$$\n\nThe posterior probability can be written as:\n$$P(A \\mid x) = \\frac{N_A}{N_A + D_T} = \\frac{1}{1 + D_T/N_A} = \\frac{1}{1 + \\frac{3}{4} \\exp(-6)}$$\n\nNow we compute the numerical value:\n$\\exp(-6) \\approx 0.00247875$\n$\\frac{3}{4} \\exp(-6) \\approx 0.75 \\times 0.00247875 \\approx 0.00185906$\n$P(A \\mid x) \\approx \\frac{1}{1 + 0.00185906} = \\frac{1}{1.00185906} \\approx 0.9981445$\n\nThe question requires the answer to be rounded to four significant figures.\n$P(A \\mid x) \\approx 0.9981$\n\nThe high posterior probability for abscess is expected, as the measured ADC value $x=0.7 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$ is only $0.5$ standard deviations away from the abscess mean ($\\mu_A=0.65 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$), but $3.5$ standard deviations away from the tumor mean ($\\mu_T=1.40 \\times 10^{-3}\\,\\text{mm}^2/\\text{s}$), making the abscess hypothesis far more likely despite the slightly lower prior probability.", "answer": "$$\\boxed{0.9981}$$", "id": "4653915"}, {"introduction": "The decision to order an imaging test extends beyond a single patient's diagnosis to encompass clinical strategy and resource allocation. The Value of Information (VOI) framework provides a rigorous method for balancing a test's diagnostic benefit against its cost. In this capstone exercise, you will use VOI principles to determine the clinical prevalence threshold at which a more sensitive but expensive test (MRI) becomes preferable to a standard one (CT) for suspected vertebral osteomyelitis, a key skill for developing evidence-based imaging guidelines [@problem_id:4653920].", "problem": "An infectious diseases service is evaluating whether to order Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) as the initial imaging modality for patients with suspected vertebral osteomyelitis. The team will use the Value of Information (VOI) perspective: the expected net benefit of a test is the expected value of improved patient outcomes attributable to information gained, minus the incremental cost of the test. Use only the following foundational elements to derive the necessary expressions: the definition of sensitivity as the probability that a test is positive given disease, the disease prevalence as the prior probability of disease in the tested population, and the principle that expected net benefit equals expected gains from correct decisions minus costs.\n\nAssume the following scientifically plausible and self-consistent quantities for the cohort presenting with suspected vertebral osteomyelitis:\n- Prevalence of vertebral osteomyelitis in the imaged cohort: $p = 0.25$.\n- Sensitivity of CT: $s_{\\mathrm{CT}} = 0.65$.\n- Sensitivity of MRI: $s_{\\mathrm{MRI}} = 0.90$.\n- Incremental acquisition cost of MRI relative to CT (that is, MRI cost minus CT cost): $\\Delta C = 800$ United States dollars.\n- Net monetary value of correctly diagnosing and treating vertebral osteomyelitis early in a true positive patient (relative to the value obtained if the diagnosis were missed at this stage), aggregating avoided complications, hospital days, and downstream care: $V = 2.0 \\times 10^{4}$ United States dollars per true positive.\n\nAssume that differences in specificity between MRI and CT do not affect net benefit in this pathway because all positive imaging results trigger confirmatory procedures that neutralize false-positive downstream costs and actions before therapy initiation. Therefore, for this decision, only the marginal gain in sensitivity affects the expected value of improved outcomes.\n\nTasks:\n1. Using the base definitions above, derive an expression for the expected incremental net monetary benefit per patient of ordering MRI instead of CT in terms of $p$, $s_{\\mathrm{MRI}}$, $s_{\\mathrm{CT}}$, $V$, and $\\Delta C$, and compute its value using the numbers provided. Express the expected benefit in United States dollars per patient and round your numerical answer to four significant figures.\n2. Determine the prevalence threshold $p^{\\ast}$ at which MRI becomes preferred over CT under this VOI framework, defined as the value of $p$ for which the expected incremental net monetary benefit is exactly zero, holding $s_{\\mathrm{MRI}}$, $s_{\\mathrm{CT}}$, $V$, and $\\Delta C$ fixed at the given values. Express $p^{\\ast}$ as a fraction and round your numerical answer to four significant figures.\n\nProvide both the computed expected incremental net monetary benefit per patient and the prevalence threshold $p^{\\ast}$.", "solution": "The problem is assessed to be valid as it is scientifically grounded in decision analysis principles, well-posed with sufficient and consistent information, and objectively stated.\n\nThe task is to derive and calculate the expected incremental net monetary benefit of choosing Magnetic Resonance Imaging (MRI) over Computed Tomography (CT) for suspected vertebral osteomyelitis, and to determine the prevalence threshold at which MRI becomes the preferred modality.\n\nLet the prevalence of vertebral osteomyelitis be $p$. Let the sensitivity of a test be $s$, defined as the probability of a positive test result given that the patient has the disease. The value of correctly diagnosing and treating a true positive case is $V$. The cost of a specific imaging test (CT or MRI) is denoted by $C_{\\text{test}}$.\n\nAccording to the problem's stated principles, the Expected Net Benefit (ENB) for a given imaging test is the expected value of improved outcomes minus the cost of the test. The improved outcome is the successful identification of a true positive, which has a monetary value of $V$.\n\nFor a single patient undergoing a test, the probability of being a true positive is the probability of having the disease, $p$, multiplied by the probability of the test correctly identifying the disease, which is the sensitivity $s$. Therefore, the expected monetary gain from a single test per patient is $p \\times s \\times V$.\n\nThe ENB for a generic test is expressed as:\n$$ \\text{ENB}_{\\text{test}} = p \\cdot s_{\\text{test}} \\cdot V - C_{\\text{test}} $$\n\nUsing this general formula, we can write the ENB for CT and MRI specifically.\nThe ENB for CT is:\n$$ \\text{ENB}_{\\mathrm{CT}} = p \\cdot s_{\\mathrm{CT}} \\cdot V - C_{\\mathrm{CT}} $$\nThe ENB for MRI is:\n$$ \\text{ENB}_{\\mathrm{MRI}} = p \\cdot s_{\\mathrm{MRI}} \\cdot V - C_{\\mathrm{MRI}} $$\n\nThe problem asks for the expected *incremental* net monetary benefit of MRI over CT, which we denote as $\\Delta \\text{ENB}$. This is the difference between the ENB of MRI and the ENB of CT.\n$$ \\Delta \\text{ENB} = \\text{ENB}_{\\mathrm{MRI}} - \\text{ENB}_{\\mathrm{CT}} $$\nSubstituting the expressions for each ENB:\n$$ \\Delta \\text{ENB} = (p \\cdot s_{\\mathrm{MRI}} \\cdot V - C_{\\mathrm{MRI}}) - (p \\cdot s_{\\mathrm{CT}} \\cdot V - C_{\\mathrm{CT}}) $$\nWe can rearrange and factor this expression:\n$$ \\Delta \\text{ENB} = (p \\cdot s_{\\mathrm{MRI}} \\cdot V - p \\cdot s_{\\mathrm{CT}} \\cdot V) - (C_{\\mathrm{MRI}} - C_{\\mathrm{CT}}) $$\n$$ \\Delta \\text{ENB} = p \\cdot V \\cdot (s_{\\mathrm{MRI}} - s_{\\mathrm{CT}}) - (C_{\\mathrm{MRI}} - C_{\\mathrm{CT}}) $$\nThe problem defines the incremental acquisition cost of MRI relative to CT as $\\Delta C = C_{\\mathrm{MRI}} - C_{\\mathrm{CT}}$. Substituting this into the equation gives the final derived expression:\n$$ \\Delta \\text{ENB} = p \\cdot V \\cdot (s_{\\mathrm{MRI}} - s_{\\mathrm{CT}}) - \\Delta C $$\nThis expression represents the expected incremental net monetary benefit per patient. The term $p \\cdot (s_{\\mathrm{MRI}} - s_{\\mathrm{CT}})$ represents the incremental probability of detecting a true positive case when using MRI instead of CT. Multiplying by $V$ gives the expected incremental gross benefit, from which the incremental cost $\\Delta C$ is subtracted.\n\n**Task 1: Compute the value of $\\Delta \\text{ENB}$**\n\nThe given values are:\n- $p = 0.25$\n- $s_{\\mathrm{CT}} = 0.65$\n- $s_{\\mathrm{MRI}} = 0.90$\n- $\\Delta C = 800$ United States dollars\n- $V = 2.0 \\times 10^{4}$ United States dollars\n\nSubstituting these values into the derived expression:\n$$ \\Delta \\text{ENB} = (0.25) \\cdot (2.0 \\times 10^{4}) \\cdot (0.90 - 0.65) - 800 $$\n$$ \\Delta \\text{ENB} = (0.25) \\cdot (20000) \\cdot (0.25) - 800 $$\n$$ \\Delta \\text{ENB} = 5000 \\cdot (0.25) - 800 $$\n$$ \\Delta \\text{ENB} = 1250 - 800 $$\n$$ \\Delta \\text{ENB} = 450 $$\nThe expected incremental net monetary benefit is $450$ dollars per patient. Rounded to four significant figures, this is $450.0$.\n\n**Task 2: Determine the prevalence threshold $p^{\\ast}$**\n\nThe prevalence threshold, $p^{\\ast}$, is the prevalence at which the expected incremental net monetary benefit is exactly zero, meaning there is no preference between MRI and CT. We find this by setting $\\Delta \\text{ENB} = 0$.\n$$ 0 = p^{\\ast} \\cdot V \\cdot (s_{\\mathrm{MRI}} - s_{\\mathrm{CT}}) - \\Delta C $$\nNow, we solve for $p^{\\ast}$:\n$$ p^{\\ast} \\cdot V \\cdot (s_{\\mathrm{MRI}} - s_{\\mathrm{CT}}) = \\Delta C $$\n$$ p^{\\ast} = \\frac{\\Delta C}{V \\cdot (s_{\\mathrm{MRI}} - s_{\\mathrm{CT}})} $$\nSubstitute the given values into this expression for the threshold prevalence:\n$$ p^{\\ast} = \\frac{800}{(2.0 \\times 10^{4}) \\cdot (0.90 - 0.65)} $$\n$$ p^{\\ast} = \\frac{800}{20000 \\cdot (0.25)} $$\n$$ p^{\\ast} = \\frac{800}{5000} $$\nAs a fraction, this simplifies to:\n$$ p^{\\ast} = \\frac{8}{50} = \\frac{4}{25} $$\nAs a decimal, this is:\n$$ p^{\\ast} = 0.16 $$\nRounded to four significant figures, this is $0.1600$. For any prevalence $p > p^{\\ast}$, the incremental benefit of MRI is positive, making it the preferred test. For $p < p^{\\ast}$, CT would be preferred.\n\nThe computed expected incremental net monetary benefit per patient is $450.0$ United States dollars, and the prevalence threshold $p^{\\ast}$ is $\\frac{4}{25}$ or $0.1600$.", "answer": "$$\\boxed{\\begin{pmatrix} 450.0 & 0.1600 \\end{pmatrix}}$$", "id": "4653920"}]}